Having trouble accessing articles? Reset your cache.

Glutamine metabolism drives PDAC

Researchers at the Dana-Farber Cancer Institute have identified a glutamine metabolism pathway that is activated by oncogenic K-Ras in pancreatic cancers.1 Moreover, the team found three different enzyme targets within the pathway that could be blocked to specifically inhibit proliferation of the malignant cells.

Cancer cells have higher metabolic demands than normal cells due to their high levels of growth and proliferation. This increased rate of glycolysis, dubbed the Warburg effect, helps sustain tumor growth.

Recent studies have shown that some oncoproteins, including c-Myc (MYC) and K-Ras, which are known to activate genes involved in cancer cell proliferation, also act as drivers for cancer metabolism.

In a 2012 paper published in Cell, a Dana-Farber team led by Alec Kimmelman identified two K-Ras-activated glucose metabolism pathways in pancreatic cancer cells. Inhibiting the pathways helped stop cancer cell proliferation.2

The K-Ras oncogene is expressed in various cancer types, including about 90% of pancreatic cancers. It is associated with poor prognosis and causes resistance to cancer drugs including epidermal

Read the full 1629 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers